Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancerCharles E. Geyer, Tanja Španić, Richard D. Gelber et al.|Annals of Oncology|2022Cited by 461